Mid-size pharma firms drive surge in biopharma M&A activity

The article notes that 2026 is shaping up as one of the busiest years for biopharma mergers and acquisitions on record.

Unlike previous years dominated by large multinational companies, a broader set of buyers is now active, including mid-cap American drugmakers, family-owned pharmaceutical groups, and European firms governed by foundations.

These mid-size players are pursuing acquisitions to expand pipelines, gain new technologies, and strengthen market positions, suggesting a shift in the M&A landscape toward more diversified participants.